These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 28968759)

  • 1. Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost.
    Ake JA; Schuetz A; Pegu P; Wieczorek L; Eller MA; Kibuuka H; Sawe F; Maboko L; Polonis V; Karasavva N; Weiner D; Sekiziyivu A; Kosgei J; Missanga M; Kroidl A; Mann P; Ratto-Kim S; Anne Eller L; Earl P; Moss B; Dorsey-Spitz J; Milazzo M; Laissa Ouedraogo G; Rizvi F; Yan J; Khan AS; Peel S; Sardesai NY; Michael NL; Ngauy V; Marovich M; Robb ML
    J Infect Dis; 2017 Nov; 216(9):1080-1090. PubMed ID: 28968759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.
    Currier JR; Ngauy V; de Souza MS; Ratto-Kim S; Cox JH; Polonis VR; Earl P; Moss B; Peel S; Slike B; Sriplienchan S; Thongcharoen P; Paris RM; Robb ML; Kim J; Michael NL; Marovich MA
    PLoS One; 2010 Nov; 5(11):e13983. PubMed ID: 21085591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.
    Nilsson C; Hejdeman B; Godoy-Ramirez K; Tecleab T; Scarlatti G; Bråve A; Earl PL; Stout RR; Robb ML; Shattock RJ; Biberfeld G; Sandström E; Wahren B
    PLoS One; 2015; 10(6):e0131748. PubMed ID: 26121679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design.
    Viegas EO; Kroidl A; Munseri PJ; Missanga M; Nilsson C; Tembe N; Bauer A; Joachim A; Joseph S; Mann P; Geldmacher C; Fleck S; Stöhr W; Scarlatti G; Aboud S; Bakari M; Maboko L; Hoelscher M; Wahren B; Robb ML; Weber J; McCormack S; Biberfeld G; Jani IV; Sandström E; Lyamuya E;
    PLoS One; 2018; 13(11):e0206838. PubMed ID: 30496299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers.
    Ramanathan VD; Kumar M; Mahalingam J; Sathyamoorthy P; Narayanan PR; Solomon S; Panicali D; Chakrabarty S; Cox J; Sayeed E; Ackland J; Verlinde C; Vooijs D; Loughran K; Barin B; Lombardo A; Gilmour J; Stevens G; Smith MS; Tarragona-Fiol T; Hayes P; Kochhar S; Excler JL; Fast P
    AIDS Res Hum Retroviruses; 2009 Nov; 25(11):1107-16. PubMed ID: 19943789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial.
    Viegas EO; Tembe N; Nilsson C; Meggi B; Maueia C; Augusto O; Stout R; Scarlatti G; Ferrari G; Earl PL; Wahren B; Andersson S; Robb ML; Osman N; Biberfeld G; Jani I; Sandström E
    AIDS Res Hum Retroviruses; 2018 Feb; 34(2):193-205. PubMed ID: 28969431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees.
    Nilsson C; Godoy-Ramirez K; Hejdeman B; Bråve A; Gudmundsdotter L; Hallengärd D; Currier JR; Wieczorek L; Hasselrot K; Earl PL; Polonis VR; Marovich MA; Robb ML; Sandström E; Wahren B; Biberfeld G
    AIDS Res Hum Retroviruses; 2014 Mar; 30(3):299-311. PubMed ID: 24090081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults.
    Mpendo J; Mutua G; Nyombayire J; Ingabire R; Nanvubya A; Anzala O; Karita E; Hayes P; Kopycinski J; Dally L; Hannaman D; Egan MA; Eldridge JH; Syvertsen K; Lehrman J; Rasmussen B; Gilmour J; Cox JH; Fast PE; Schmidt C
    PLoS One; 2015; 10(8):e0134287. PubMed ID: 26252526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults.
    Joachim A; Nilsson C; Aboud S; Bakari M; Lyamuya EF; Robb ML; Marovich MA; Earl P; Moss B; Ochsenbauer C; Wahren B; Mhalu F; Sandström E; Biberfeld G; Ferrari G; Polonis VR
    PLoS One; 2015; 10(4):e0118486. PubMed ID: 25874723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial.
    Frank I; Li SS; Grunenberg N; Overton ET; Robinson ST; Zheng H; Seaton KE; Heptinstall JR; Allen MA; Mayer KH; Culver DA; Keefer MC; Edupuganti S; Pensiero MN; Mehra VL; De Rosa SC; Morris DE; Wang S; Seaman MS; Montefiori DC; Ferrari G; Tomaras GD; Kublin JG; Corey L; Lu S;
    Lancet HIV; 2024 May; 11(5):e285-e299. PubMed ID: 38692824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap.
    Gray GE; Mayer KH; Elizaga ML; Bekker LG; Allen M; Morris L; Montefiori D; De Rosa SC; Sato A; Gu N; Tomaras GD; Tucker T; Barnett SW; Mkhize NN; Shen X; Downing K; Williamson C; Pensiero M; Corey L; Williamson AL
    Clin Vaccine Immunol; 2016 Jun; 23(6):496-506. PubMed ID: 27098021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial.
    Hayton EJ; Rose A; Ibrahimsa U; Del Sorbo M; Capone S; Crook A; Black AP; Dorrell L; Hanke T
    PLoS One; 2014; 9(7):e101591. PubMed ID: 25007091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers.
    Joachim A; Munseri PJ; Nilsson C; Bakari M; Aboud S; Lyamuya EF; Tecleab T; Liakina V; Scarlatti G; Robb ML; Earl PL; Moss B; Wahren B; Mhalu F; Ferrari G; Sandstrom E; Biberfeld G
    AIDS Res Hum Retroviruses; 2017 Aug; 33(8):880-888. PubMed ID: 28027665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
    Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
    J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials.
    Moodie Z; Walsh SR; Laher F; Maganga L; Herce ME; Naidoo S; Hosseinipour MC; Innes C; Bekker LG; Grunenberg N; Mann P; Yu C; deCamp AC; Miner MD; Yates NL; Heptinstall J; Mkhize NN; Dintwe O; Frahm N; Cohen KW; Allen M; Hutter J; Wagner R; Pantaleo G; McElrath MJ; Tomaras GD; Morris L; Montefiori DC; Andersen-Nissen E; Gray GE; Gilbert PB; Kublin JG;
    PLoS Med; 2020 May; 17(5):e1003117. PubMed ID: 32442195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines.
    Laher F; Moodie Z; Cohen KW; Grunenberg N; Bekker LG; Allen M; Frahm N; Yates NL; Morris L; Malahleha M; Mngadi K; Daniels B; Innes C; Saunders K; Grant S; Yu C; Gilbert PB; Phogat S; DiazGranados CA; Koutsoukos M; Van Der Meeren O; Bentley C; Mkhize NN; Pensiero MN; Mehra VL; Kublin JG; Corey L; Montefiori DC; Gray GE; McElrath MJ; Tomaras GD
    PLoS Med; 2020 Feb; 17(2):e1003038. PubMed ID: 32092060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers.
    Cebere I; Dorrell L; McShane H; Simmons A; McCormack S; Schmidt C; Smith C; Brooks M; Roberts JE; Darwin SC; Fast PE; Conlon C; Rowland-Jones S; McMichael AJ; Hanke T
    Vaccine; 2006 Jan; 24(4):417-25. PubMed ID: 16176847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults.
    Buchbinder SP; Grunenberg NA; Sanchez BJ; Seaton KE; Ferrari G; Moody MA; Frahm N; Montefiori DC; Hay CM; Goepfert PA; Baden LR; Robinson HL; Yu X; Gilbert PB; McElrath MJ; Huang Y; Tomaras GD;
    PLoS One; 2017; 12(7):e0179597. PubMed ID: 28727817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.
    Goepfert PA; Elizaga ML; Sato A; Qin L; Cardinali M; Hay CM; Hural J; DeRosa SC; DeFawe OD; Tomaras GD; Montefiori DC; Xu Y; Lai L; Kalams SA; Baden LR; Frey SE; Blattner WA; Wyatt LS; Moss B; Robinson HL;
    J Infect Dis; 2011 Mar; 203(5):610-9. PubMed ID: 21282192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization with multiple vaccine modalities induce strong HIV-specific cellular and humoral immune responses.
    Hallengärd D; Applequist SE; Nyström S; Maltais AK; Marovich M; Moss B; Earl P; Nihlmark K; Wahren B; Bråve A
    Viral Immunol; 2012 Oct; 25(5):423-32. PubMed ID: 23035853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.